Abstract
Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition - and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia,
Keywords: Eosinophilia, interferon, treatment, classification, review, pure idiopathic hypereosinophilia, hypereosinophilia, cyclophosphamide
Current Drug Targets
Title: Interferon Treatment in Patients with Hypereosinophilia
Volume: 12 Issue: 3
Author(s): Ole Weis Bjerrum
Affiliation:
Keywords: Eosinophilia, interferon, treatment, classification, review, pure idiopathic hypereosinophilia, hypereosinophilia, cyclophosphamide
Abstract: Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition - and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia,
Export Options
About this article
Cite this article as:
Weis Bjerrum Ole, Interferon Treatment in Patients with Hypereosinophilia, Current Drug Targets 2011; 12 (3) . https://dx.doi.org/10.2174/138945011794815211
DOI https://dx.doi.org/10.2174/138945011794815211 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets HIV-1 Infection In Children: A Clinical and Immunologic Overview
Current HIV Research Analytical Methods for the Quantification of Selenium Species in Biological Matrix: Where are We?
Current Nutraceuticals GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Mechanical Circulatory Support of the Critically Ill Child Awaiting Heart Transplantation
Current Cardiology Reviews Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy
Current Cardiology Reviews